Fujita Yasuyuki, Kawamoto Atsuhiko
Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Hyogo, Japan.
Ann Vasc Dis. 2022 Dec 25;15(4):241-252. doi: 10.3400/avd.ra.22-00086.
CD34 is a cell surface marker, which is expressed in various somatic stem/progenitor cells such as bone marrow (BM)-derived hematopoietic stem cells and endothelial progenitor cells (EPCs), skeletal muscle satellite cells, epithelial hair follicle stem cells, and adipose tissue mesenchymal stem cells. CD34+ cells in BM and peripheral blood are known as a rich source of EPCs. Thus, vascular regeneration therapy using granulocyte colony stimulating factor (G-CSF) mobilized- or BM CD34+ cells has been carried out in patients with various vascular diseases such as chronic severe lower limb ischemia, acute myocardial infarction, refractory angina, ischemic cardiomyopathy, and dilated cardiomyopathy as well as ischemic stroke. Pilot and randomized clinical trials demonstrated the safety, feasibility, and effectiveness of the CD34+ cell therapy in peripheral arterial, cardiovascular, and cerebrovascular diseases. This review provides an overview of the preclinical and clinical reports of CD34+ cell therapy for vascular regeneration.
CD34是一种细胞表面标志物，在多种体干细胞/祖细胞中表达，如骨髓（BM）来源的造血干细胞、内皮祖细胞（EPCs）、骨骼肌卫星细胞、上皮毛囊干细胞和脂肪组织间充质干细胞。骨髓和外周血中的CD34+细胞是EPCs的丰富来源。因此，已在患有各种血管疾病的患者中开展了使用粒细胞集落刺激因子（G-CSF）动员的或骨髓CD34+细胞的血管再生治疗，这些疾病包括慢性重度下肢缺血、急性心肌梗死、难治性心绞痛、缺血性心肌病、扩张型心肌病以及缺血性中风。先导性和随机临床试验证明了CD34+细胞疗法在周围动脉、心血管和脑血管疾病中的安全性、可行性和有效性。本综述概述了CD34+细胞疗法用于血管再生的临床前和临床报告。
